JP2016535787A - 新規方法 - Google Patents

新規方法 Download PDF

Info

Publication number
JP2016535787A
JP2016535787A JP2016552485A JP2016552485A JP2016535787A JP 2016535787 A JP2016535787 A JP 2016535787A JP 2016552485 A JP2016552485 A JP 2016552485A JP 2016552485 A JP2016552485 A JP 2016552485A JP 2016535787 A JP2016535787 A JP 2016535787A
Authority
JP
Japan
Prior art keywords
compound
formula
treated
edema
aquaporin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2016552485A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016535787A5 (enExample
Inventor
マーク・エフ・ペレティエ
ポール・ロバート・マクガーク
ジョージ・ウィリアム・ファー
スティーブン・ウィリアムズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeromics Inc
Original Assignee
Aeromics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeromics Inc filed Critical Aeromics Inc
Publication of JP2016535787A publication Critical patent/JP2016535787A/ja
Publication of JP2016535787A5 publication Critical patent/JP2016535787A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
JP2016552485A 2013-11-06 2014-11-06 新規方法 Ceased JP2016535787A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361900919P 2013-11-06 2013-11-06
US201361900878P 2013-11-06 2013-11-06
US201361900946P 2013-11-06 2013-11-06
US61/900,878 2013-11-06
US61/900,919 2013-11-06
US61/900,946 2013-11-06
PCT/US2014/064432 WO2015069948A1 (en) 2013-11-06 2014-11-06 Novel methods

Publications (2)

Publication Number Publication Date
JP2016535787A true JP2016535787A (ja) 2016-11-17
JP2016535787A5 JP2016535787A5 (enExample) 2017-12-14

Family

ID=53042097

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016552485A Ceased JP2016535787A (ja) 2013-11-06 2014-11-06 新規方法
JP2016552486A Active JP6535338B2 (ja) 2013-11-06 2014-11-06 新規製剤
JP2019102367A Active JP6957557B2 (ja) 2013-11-06 2019-05-31 新規製剤
JP2021164647A Pending JP2022003084A (ja) 2013-11-06 2021-10-06 新規製剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016552486A Active JP6535338B2 (ja) 2013-11-06 2014-11-06 新規製剤
JP2019102367A Active JP6957557B2 (ja) 2013-11-06 2019-05-31 新規製剤
JP2021164647A Pending JP2022003084A (ja) 2013-11-06 2021-10-06 新規製剤

Country Status (14)

Country Link
US (9) US9827253B2 (enExample)
EP (3) EP3065729A4 (enExample)
JP (4) JP2016535787A (enExample)
KR (1) KR20160079109A (enExample)
CN (3) CN106163506A (enExample)
AU (2) AU2014346682B2 (enExample)
CA (1) CA2929821A1 (enExample)
ES (1) ES2834131T3 (enExample)
HK (1) HK1224228A1 (enExample)
IL (1) IL245420B (enExample)
MX (2) MX386250B (enExample)
RU (1) RU2691951C2 (enExample)
SG (1) SG11201604153UA (enExample)
WO (3) WO2015069956A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021023226A (ja) * 2019-08-06 2021-02-22 学校法人慶應義塾 アクアポリン活性調節剤候補のハイスループットスクリーニング方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104602682B (zh) 2012-05-08 2018-12-14 埃罗米克斯公司 用于治疗水通道蛋白介导的疾病的化合物
EP3065729A4 (en) 2013-11-06 2017-05-31 Aeromics, Inc. Novel formulations
AU2017261828B2 (en) * 2016-05-13 2023-04-13 Aeromics, Inc. Crystals
CN110790787B (zh) * 2019-11-12 2022-06-14 广东药科大学 一类水溶性前药、其制备方法及其作为药物的用途
BR112023002129A2 (pt) * 2020-08-05 2023-04-18 Jiangsu Simcere Pharm Co Ltd Composição farmacêutica de inibidor de aquaporina e método de preparação da mesma
CN117105810B (zh) * 2023-10-23 2024-02-09 中国农业大学 一种具有广谱抗菌活性的化合物及其抗菌组合物
CN118178653B (zh) * 2024-03-22 2026-02-06 山东第一医科大学附属省立医院(山东省立医院) 跨膜水交换蛋白aqp4抑制剂在制备抗脑胶质瘤药物上的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003103656A1 (ja) * 2002-06-06 2003-12-18 株式会社医薬分子設計研究所 Ｏ−置換ヒドロキシアリール誘導体
WO2003103657A1 (ja) * 2002-06-11 2003-12-18 株式会社医薬分子設計研究所 神経変性疾患治療剤
WO2003103654A1 (ja) * 2002-06-10 2003-12-18 株式会社医薬分子設計研究所 ＮＦ−κＢ活性化阻害剤
WO2010101648A1 (en) * 2009-03-06 2010-09-10 Wood Richard D Glutamate receptor modulators and therapeutic agents
JP2011506416A (ja) * 2007-12-13 2011-03-03 ユニバーシティ オブ ダンディー 医療用シグマリガンド及びＩＫＫ／ＮＦ−κＢ阻害剤
JP2015520151A (ja) * 2012-05-08 2015-07-16 エアロミクス・リミテッド・ライアビリティ・カンパニーＡｅｒｏｍｉｃｓ，ＬＬＣ 新規方法

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE615511A (enExample) 1961-03-25
NL292958A (enExample) 1962-05-29 1900-01-01
GB8809205D0 (en) 1988-04-19 1988-05-25 Nye P C G Treatment of oedema
US5137871A (en) 1989-07-28 1992-08-11 Regents Of The University Of California Treatment to reduce edema for brain and musculature injuries
DE4010536A1 (de) * 1990-04-02 1991-10-10 Boehringer Mannheim Gmbh Pharmazeutische waessrige loesung von 4-(2-(benzolsulfonylamino)-ethyl)-phenoxyessigsaeure
US5486530A (en) 1991-04-27 1996-01-23 Boehringer Mannheim Gmbh Use of torasemide for the treatment of brain oedemas
DE4113820A1 (de) 1991-04-27 1992-10-29 Boehringer Mannheim Gmbh Verwendung von torasemid zur behandlung von hirnoedemen
US5741671A (en) 1991-12-12 1998-04-21 The Johns Hopkins University Isolation cloning and expression of transmembrane water channel aquaporin 1(AQP1)
US5858702A (en) 1991-12-13 1999-01-12 The Johns Hopkins University Isolation, cloning and expression of transmembrane water channel Aquaporin 5 (AQP5)
US5519035A (en) 1993-07-02 1996-05-21 Cornell Research Foundation, Inc. Treatment of stroke or in anticipation of the occurrence of brain ischemia
US20060167110A1 (en) 1995-01-13 2006-07-27 Blume Cherly D Methods for treating cerebrovascular disease by administering desmethylselegiline
WO1998021951A1 (en) 1996-11-18 1998-05-28 Emisphere Technologies, Inc. Methods and compositions for inducing oral tolerance in mammals
EP1005347A4 (en) 1997-08-06 2002-08-28 Smithkline Beecham Corp ANTAGONISTS OF THE RECEPTORS OF THE MONOCYTE MACROPHAGE FOR USE IN TREATING CARDIOVASCULAR DISEASES
US5905090A (en) 1998-04-29 1999-05-18 Italfarmaco S.P.A. Analogues of the active metabolite of leflunomide
CO5180581A1 (es) * 1999-09-30 2002-07-30 Pfizer Prod Inc Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
US6500809B1 (en) 1999-11-12 2002-12-31 Neuron Therapeutics, Inc. Hyperoncotic artificial cerebrospinal fluid and method of treating neural tissue edema therewith
DK1106614T3 (da) 1999-12-10 2004-04-13 Pfizer 5-leddede, heteroarylsubstituerede 1,4-dihydropyridinforbindelser som bradykininantagonister
WO2002049632A1 (en) 2000-12-18 2002-06-27 Institute Of Medicinal Molecular Design. Inc. Inhibitors against the production and release of inflammatory cytokines
ES2807274T3 (es) 2002-03-20 2021-02-22 Univ Maryland Un canal catiónico no selectivo en células neurales y compuestos que bloquean el canal para su uso en el tratamiento de la inflamación del cerebro
US8980952B2 (en) 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
WO2003103658A1 (ja) 2002-06-05 2003-12-18 株式会社医薬分子設計研究所 免疫関連プロテインキナーゼ阻害剤
EA009523B1 (ru) 2002-06-05 2008-02-28 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Ингибиторы в отношении активации ар-1 и nfat
CA2488342A1 (en) 2002-06-05 2003-12-18 Institute Of Medicinal Molecular Design, Inc. Therapeutic drug for diabetes
AU2003242103A1 (en) 2002-06-06 2003-12-22 Institute Of Medicinal Molecular Design, Inc Antiallergic agents
EA010835B1 (ru) 2002-06-10 2008-12-30 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Лекарственное средство для лечения рака
EP1542699A4 (en) 2002-07-15 2009-03-25 Myriad Genetics Inc COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
DK1590458T3 (da) 2003-02-06 2013-02-04 Univ Belfast Bradykinin B2-receptorantagonistpeptid fra amfibiehud
SI1617834T1 (sl) 2003-05-01 2007-02-28 Innogene Kalbiotech Pte Ltd Uporaba farmacevtskega sestavka, ki vsebuje mlecno kislino ali laktat in kalij, za zdravljenje mozganskega edema in mozganske poskodbe
US20070042997A1 (en) 2003-07-16 2007-02-22 Akiko Itai Medicament for treatment of dermal pigmentation
US7598412B2 (en) * 2003-10-08 2009-10-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8467876B2 (en) 2003-10-15 2013-06-18 Rmx, Llc Breathing disorder detection and therapy delivery device and method
US20070254956A1 (en) 2003-10-29 2007-11-01 Koichi Shudo Medicament for Therapeutic and/or Preventive Treatment of Restenosis or Reocclusion After Vascular Recanalization Operation
US7378509B2 (en) 2003-12-02 2008-05-27 Anesiva, Inc. NF-kappaB oligonucleotide decoy molecules
US10583094B2 (en) 2004-09-18 2020-03-10 University Of Maryland Therapeutic methods that target the NCCA-ATP channel
JP5085326B2 (ja) 2004-09-18 2012-11-28 ユニバーシティ オブ メリーランド，ボルチモア ＮＣＣａ−ＡＴＰチャネルを標的とする処置剤およびその使用方法
US7601745B2 (en) 2004-09-27 2009-10-13 4Sc Ag Heterocyclic NF-kB inhibitors
AU2006204146A1 (en) 2005-01-04 2006-07-13 Novartis Ag Biomarkers for identifying efficacy of tegaserod in patients with chronic constipation
MY147790A (en) 2005-04-28 2013-01-31 Takeda Pharmaceutical Stable emulsion composition
WO2007084464A2 (en) 2006-01-17 2007-07-26 The University Of North Carolina At Chapel Hill Water channel blockers and methods of use thereof
JP4273235B2 (ja) * 2006-06-01 2009-06-03 国立大学法人 新潟大学 アクアポリン４阻害薬
JP2009539870A (ja) 2006-06-06 2009-11-19 ジェネンテック・インコーポレーテッド 血管発生の調節ための組成物および方法
AU2007319672B2 (en) 2006-06-06 2011-06-30 Genentech, Inc. Anti-DLL4 antibodies and methods using same
US7671058B2 (en) 2006-06-21 2010-03-02 Institute Of Medicinal Molecular Design, Inc. N-(3,4-disubstituted phenyl) salicylamide derivatives
US10004703B2 (en) 2006-10-12 2018-06-26 Biogen Chesapeake Llc Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels
US20100056444A1 (en) 2006-10-12 2010-03-04 Sven Martin Jacobson Treatment of Alzheimer's Disease Using Compounds that Reduce the Activity of Non Selective Ca Activated ATP- Sensitive Cation Channels Regulated by SUR1 Receptors
EP2086329B1 (en) 2006-10-26 2014-07-23 The Arizona Board of Regents on behalf of the University of Arizona Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance
US9316633B2 (en) 2006-11-16 2016-04-19 The Regents Of The University Of California Methods for identifying inhibitors of solute transporters
US20080171719A1 (en) 2006-11-28 2008-07-17 Alcon Manufacturing, Ltd. RNAi-MEDIATED INHIBITION OF AQUAPORIN 1 FOR TREATMENT OF IOP-RELATED CONDITIONS
US20080214486A1 (en) 2006-11-28 2008-09-04 Alcon Manufacturing, Ltd. RNAi-MEDIATED INHIBITION OF AQUAPORIN 4 FOR TREATMENT OF IOP-RELATED CONDITIONS
WO2008089103A2 (en) 2007-01-12 2008-07-24 University Of Maryland, Baltimore Targeting ncca-atp channel for organ protection following ischemic episode
SG178716A1 (en) 2007-01-16 2012-03-29 Ipintl Llc Novel composition for treating metabolic syndrome
US20120183600A1 (en) * 2007-01-16 2012-07-19 Chien-Hung Chen Novel composition for treating metabolic syndrome and other conditions
US20100092469A1 (en) 2007-02-09 2010-04-15 Simard J Marc Antagonists of a non-selective cation channel in neural cells
EP2543249B1 (en) 2007-02-17 2018-05-23 President and Fellows of Harvard College Compositions and method for tissue preservation
TW200848063A (en) 2007-04-23 2008-12-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
CA2691199C (en) 2007-06-22 2017-09-12 Marc J. Simard Inhibitors of ncca-atp channels for therapy
AU2008272818A1 (en) * 2007-07-02 2009-01-08 Yu, Ming Dr Methods, composition, targets for combinational cancer treatments
US20090239868A1 (en) 2007-10-23 2009-09-24 Institute Of Medical Molecular Design, Inc. Inhibitor of pai-1 production
WO2009054439A1 (ja) 2007-10-23 2009-04-30 Institute Of Medicinal Molecular Design, Inc. Pai-1産生抑制剤
CA3123813C (en) 2007-12-04 2024-10-08 Remedy Pharmaceuticals, Inc. IMPROVED GLIBENCLAMIDE FORMULATIONS AND RELATED FREEZE-DRYING METHODS, AND FREEZE-DRY SATE PRODUCED THUS
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009097443A2 (en) 2008-01-29 2009-08-06 Remedy Pharmaceuticals, Inc. Liquid formulations of compounds active at sulfonylurea receptors
US20090286799A1 (en) 2008-05-16 2009-11-19 Zhi-Gang Jiang Methods for the treatment of brain edema
US20110263478A1 (en) 2008-09-16 2011-10-27 Simard J Marc Sur1 inhibitors for therapy
US20120010178A1 (en) 2008-10-21 2012-01-12 President And Fellows Of Harvard College Methods and compounds for treatment of neurodegenerative disorders
GB0823366D0 (en) 2008-12-22 2009-01-28 Uni I Oslo Synthesis
CN102348668B (zh) 2009-01-12 2014-11-19 培力有限公司 化合物及其用于治疗炎症和调节免疫应答的用途
US20120039805A1 (en) 2009-02-20 2012-02-16 Pangea Biosciences, Inc. Therapeutics And Methods For Treating Neoplastic Diseases Comprising Determining The Level Of Caveolin-1 And/Or Caveolin-2 In A Stromal Cell Sample
KR101800040B1 (ko) 2010-03-10 2017-11-21 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 릴랙신을 사용한 아쿠아포린의 조절
CA2806069C (en) 2010-07-19 2021-01-19 Remedy Pharmaceuticals, Inc. Methods of intravenous administration of glyburide and other drugs
JP2013535457A (ja) * 2010-07-28 2013-09-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系及び炎症性疾患の治療用医薬組成物
US20110052678A1 (en) 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration
EP2685972A4 (en) 2011-03-14 2014-08-13 Io Therapeutics Inc TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES WITH RAR ALPHA SELECTIVE AGONISTS
ES2622112T3 (es) 2011-05-02 2017-07-05 Stichting Vumc Protección contra la disfunción de la barrera endotelial a través de la inhibición del gen relacionado con la tirosina quinasa Abl (ARG)
RU2461375C1 (ru) * 2011-05-19 2012-09-20 Учреждение Российской академии медицинских наук Научно-исследовательский институт онкологии Сибирского отделения Российской академии медицинских наук (НИИ онкологии СО РАМН) Способ комбинированного лечения больных местно-распространенным раком желудка
WO2013152313A1 (en) * 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
US9452973B2 (en) 2012-05-04 2016-09-27 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Modulators of the relaxin receptor 1
JP6083770B2 (ja) 2013-09-13 2017-02-22 昭子 板井 水溶液製剤及びその製造方法
EP3065729A4 (en) 2013-11-06 2017-05-31 Aeromics, Inc. Novel formulations
SG11201604477SA (en) 2013-12-13 2016-07-28 Vertex Pharma Prodrugs of pyridone amides useful as modulators of sodium channels
AU2015346076A1 (en) 2014-11-13 2017-06-15 Aeromics, Inc. Novel methods
CN108348567B (zh) 2015-05-29 2022-03-01 马里兰州立大学巴尔的摩分校 减少或预防由内皮细胞的机械刺激所致的内膜损伤的方法
KR20240105519A (ko) 2015-10-07 2024-07-05 레메디 파마슈티칼즈, 인크. Cns 부종과 관련한 손상 또는 병태의 치료 방법
AU2017261828B2 (en) 2016-05-13 2023-04-13 Aeromics, Inc. Crystals
JP7165648B2 (ja) 2016-07-29 2022-11-04 バイオジェン チェサピーク エルエルシー Ｓｕｒ１－ｔｒｐｍ４チャネル阻害剤による医療処置方法
BR112023002129A2 (pt) 2020-08-05 2023-04-18 Jiangsu Simcere Pharm Co Ltd Composição farmacêutica de inibidor de aquaporina e método de preparação da mesma

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003103656A1 (ja) * 2002-06-06 2003-12-18 株式会社医薬分子設計研究所 Ｏ−置換ヒドロキシアリール誘導体
WO2003103654A1 (ja) * 2002-06-10 2003-12-18 株式会社医薬分子設計研究所 ＮＦ−κＢ活性化阻害剤
WO2003103657A1 (ja) * 2002-06-11 2003-12-18 株式会社医薬分子設計研究所 神経変性疾患治療剤
JP2011506416A (ja) * 2007-12-13 2011-03-03 ユニバーシティ オブ ダンディー 医療用シグマリガンド及びＩＫＫ／ＮＦ−κＢ阻害剤
WO2010101648A1 (en) * 2009-03-06 2010-09-10 Wood Richard D Glutamate receptor modulators and therapeutic agents
JP2015520151A (ja) * 2012-05-08 2015-07-16 エアロミクス・リミテッド・ライアビリティ・カンパニーＡｅｒｏｍｉｃｓ，ＬＬＣ 新規方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021023226A (ja) * 2019-08-06 2021-02-22 学校法人慶應義塾 アクアポリン活性調節剤候補のハイスループットスクリーニング方法

Also Published As

Publication number Publication date
US20180169118A1 (en) 2018-06-21
CN106163506A (zh) 2016-11-23
US20160279155A1 (en) 2016-09-29
US20210275549A1 (en) 2021-09-09
US20160264604A1 (en) 2016-09-15
US9827253B2 (en) 2017-11-28
US20220143048A1 (en) 2022-05-12
AU2020203697A1 (en) 2020-06-25
JP2019163314A (ja) 2019-09-26
EP3065727A1 (en) 2016-09-14
CN112370456A (zh) 2021-02-19
AU2014346682B2 (en) 2020-03-12
EP3065729A4 (en) 2017-05-31
JP2016536370A (ja) 2016-11-24
WO2015069961A1 (en) 2015-05-14
WO2015069948A1 (en) 2015-05-14
JP6535338B2 (ja) 2019-06-26
MX2021008629A (es) 2021-08-19
EP3065727A4 (en) 2017-05-31
ES2834131T3 (es) 2021-06-16
US11071744B2 (en) 2021-07-27
US12496308B2 (en) 2025-12-16
US20190307779A1 (en) 2019-10-10
EP3065728A1 (en) 2016-09-14
RU2016121850A (ru) 2017-12-08
HK1224228A1 (zh) 2017-08-18
IL245420A0 (en) 2016-06-30
RU2016121850A3 (enExample) 2018-08-08
MX386250B (es) 2025-03-18
WO2015069956A2 (en) 2015-05-14
JP2022003084A (ja) 2022-01-11
EP3065727B1 (en) 2020-08-26
CN112402434A (zh) 2021-02-26
US9949991B2 (en) 2018-04-24
EP3065728A4 (en) 2017-06-07
RU2691951C2 (ru) 2019-06-19
US20200297740A1 (en) 2020-09-24
BR112016010338A2 (pt) 2017-08-08
US10894055B2 (en) 2021-01-19
CA2929821A1 (en) 2015-05-14
US12213987B2 (en) 2025-02-04
US20240299425A1 (en) 2024-09-12
KR20160079109A (ko) 2016-07-05
US10258636B2 (en) 2019-04-16
AU2014346682A1 (en) 2016-06-09
IL245420B (en) 2020-10-29
MX2016006012A (es) 2016-12-09
EP3065729A2 (en) 2016-09-14
US11801254B2 (en) 2023-10-31
US20160346302A1 (en) 2016-12-01
SG11201604153UA (en) 2016-07-28
WO2015069956A3 (en) 2015-11-12
JP6957557B2 (ja) 2021-11-02

Similar Documents

Publication Publication Date Title
JP6570597B2 (ja) 新規方法
US9949991B2 (en) Methods of treating aquaporin-mediated conditions
CN104869993B (zh) 治疗阿尔茨海默病及相关疾病的组合疗法
JP2013528198A (ja) １型糖尿病の処置
EP2882431B1 (en) Probenecid for treating decompensated heart failure
HK1208363B (en) Compounds for use in the treatment of aquaporin-mediated diseases
HK40053435A (en) Probenecid for treating decompensated heart failure

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180828

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181210

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190402

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20190827